from Reuters: Health News https://ift.tt/2rNxuFQ
Loxo Oncology's targeted RET drug shows promise in early trial
CHICAGO (Reuters) - An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.
from Reuters: Health News https://ift.tt/2rNxuFQ
from Reuters: Health News https://ift.tt/2rNxuFQ
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment